This 12th biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials in the field of hemato-oncology, covering the publication period from September 1, 2009, through June 30, 2010. Implication for clinical practice and methodological aspects are the main principles used to select trials for this report. Studies on tyrosine kinase inhibitors for patients with chronic myeloid leukemia were identified through electronic search of MEDLINE with a broad search filter that covered all topics in hemato-oncology combined with a highly sensitive search filter for randomized studies as described in the Cochrane Handbook for Systematic Reviews of Interventions. © The Author 2011. Published by Oxford University Press.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Skoetz, N., Kluge, S., Monsef, I., Bauer, K., Siebert, H., Kreuzer, K. A., & Engert, A. (2011, February 16). Twelfth biannual report of the Cochrane Haematological Malignancies Group - Focus on tyrosine kinase inhibitors. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djq531